What's Next For Phase II ADCs

BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.    

Antibody Drug Conjugate
• Source: Shutterstock

Antibody-drug conjugates are big business and major deals have been struck in this area over the past year or so, with companies including Pfizer Inc., Johnson & Johnson and Merck & Co., Inc. all buying in examples of this technology.

Key Takeaways
  • A handful of antibody-drug conjugates are in Phase II trials, with several readouts coming in the next couple of years.

But one group has thought better of a similar move. On 1 July, Bristol Myers Squibb Company pulled out...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

More from R&D